Oncotarget

Research Papers:

Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN

Tian-Huei Chu, Hoi-Hung Chan, Hsiao-Mei Kuo, Li-Fen Liu, Tsung-Hui Hu, Cheuk-Kwan Sun, Mei-Lang Kung, Shih-Wei Lin, E-Ming Wang, Yi-Ling Ma, Kwan-Hung Cheng, Kwok-Hung Lai, Zhi-Hong Wen, Ping-I Hsu and Ming-Hong Tai _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:1475-1490. https://doi.org/10.18632/oncotarget.1745

Metrics: PDF 2132 views  |   HTML 2281 views  |   ?  


Abstract

Tian-Huei Chu1,*, Hoi-Hung Chan2,3,4,5,*, Hsiao-Mei Kuo6, Li-Fen Liu7, Tsung-Hui Hu8, Cheuk-Kwan Sun9, Mei-Lang Kung10, Shih-Wei Lin11, E-Ming Wang2,3, Yi-Ling Ma2, Kwan-Hung Cheng1, Kwok Hung Lai3,4, Zhi-Hong Wen13, Ping-I Hsu3,4 and Ming-Hong Tai1,2,14

1 Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan

2 Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan

3 Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

4 School of Medicine, National Yang-Ming University, Taipei, Taiwan

5 College of Pharmacy & Health Care, Tajen University, Pingtung County, Taiwan

6 Mitochondrial Research Unit, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

7 Department of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan

8 Division of Hepato-Gastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan

9 Department of Medical Education, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan

10 Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan

11 Institute of Marine Biotechnology, National Sun Yat-sen University, Kaohsiung, Taiwan

12 Department of Medical Education; Digestive Center, E-DA Hospital, Kaohsiung County, Taiwan

13 Department of Marine Biotechnology and Resources, Asia-Pacific Ocean Research Center, National Sun Yat-Sen University, Kaohsiung, Taiwan

14 Center for Neuroscience, National Sun Yat-Sen University, Kaohsiung 804, Taiwan

* These authors contributed equally to this work

Correspondence:

Ming-Hong Tai, email:

Keywords: hepatocellular carcinoma, hepatic cancer stem cells, celecoxib, prostaglandin E2, phosphatase and tensin homolog.

Received: September 4, 2013 Accepted: December 28, 2013 Published: December 28, 2013

Abstract

Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib suppressed the self-renewal and drug-pumping functions in HCC cells. Besides, celecoxib depleted CD44+/CD133+ hepatic cancer stem cells (hCSC). Prostaglandin E2 (PGE2) and CD133 overexpression did not reverse the celecoxib-induced depletion of hCSC. Also, celecoxib inhibited progression of rat Novikoff hepatoma. Moreover, a 60-day celecoxib program increased the survival rate of rats with hepatoma. Histological analysis revealed that celecoxib therapy reduced the abundance of CD44+/CD133+ hCSCs in hepatoma tissues. Besides, the hCSCs depletion was associated with elevated apoptosis and blunted proliferation and angiogenesis in hepatoma. Celecoxib therapy activated peroxisome proliferator-activated receptor γ (PPARγ) and up-regulated PTEN, thereby inhibiting Akt and disrupting hCSC expansion. PTEN gene delivery by adenovirus reduced CD44/CD133 expression in vitro and hepatoma formation in vivo. This study suggests that celecoxib suppresses cancer stemness and progression of HCC via activation of PPARγ/PTEN signaling.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1745